Latest News-CliniExpert

FDA Approves Qelbree (viloxazine) for the Treatment of ADHD

ROCKVILLE, Md., April 02, 2021 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of ce

Sputnik V Authorized in 26 Countries

Moscow, February 12, 2021 -- The Russian Direct Investment Fund (RDIF, Russia’s sovereign wealth fund) announces the approval of Russian Sputnik V vaccine against coronavirus in Montenegro and Saint V

Pfizer and BioNTech to Supply the United States with 100 Million Additional Doses of COVID-19 Vaccine

NEW YORK and MAINZ, GERMANY, February 12, 2021 -- Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced that the U.S. government has exercised its option for an additional 100 million

Canada Purchases Additional 4 Million Doses of Moderna’s COVID-19 Vaccine

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Feb. 12, 2021 -- Moderna, Inc., (Nasdaq: MRNA) a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced that the Canadian G

Four Potential COVID-19 Therapeutics Enter Phase 2/3 Testing in NIH ACTIV-2 Trial

February 12, 2021 -- Enrollment has begun to test additional investigational drugs in the Accelerating COVID-19 Therapeutic Interventions and Vaccines (ACTIV) program. ACTIV is a public-private partne

Qatar Ministry of Public Health Issues Emergency Use Authorization for COVID-19 Vaccine Moderna

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Feb. 11, 2021 -- Moderna, Inc. (Nasdaq: MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced that the Qatar Mini

New Phase III Data Show Genentech’s Faricimab Is the First Investigational Injectable Eye Medicine to Extend Time Between Treatments up to Four Months in Two Leading Causes of Vision Loss, Potentially Reducing Treatment Burden for Patients

South San Francisco, CA -- February 11, 2021 -- Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY) today announced detailed results from four Phase III studies of its investigational

U.S. Government Purchases Additional 100 Million Doses of Moderna’s COVID-19 Vaccine

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Feb. 11, 2021 -- Moderna, Inc., (Nasdaq: MRNA) a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced that the U.S. gover

PaxMedica Announces Positive Results from Phase 2 Trial of PAX-101 (IV suramin) in Children with Autism Spectrum Disorder (ASD)

WOODCLIFF LAKE, N.J., Feb. 9, 2021 /PRNewswire/ -- PaxMedica, Inc. ("PaxMedica" or the "Company"), a biopharmaceutical company focused on the development and commercialization of i

Lilly's Bamlanivimab (LY-CoV555) Administered with Etesevimab (LY-CoV016) Receives FDA Emergency Use Authorization for COVID-19

INDIANAPOLIS, Feb. 9, 2021 /PRNewswire/ -- The U.S. Food and Drug Administration (FDA) granted Emergency Use Authorization (EUA) for investigational bamlanivimab (LY-CoV555) 700 mg and etesevimab (LY-

FDA Approves Abecma (idecabtagene vicleucel) as the First Anti-BCMA CAR T Cell Therapy for Relapsed or Refractory Multiple Myeloma

PRINCETON, N.J., & CAMBRIDGE, Mass.--(BUSINESS WIRE) March 26, 2021 -- Bristol Myers Squibb (NYSE: BMY) and bluebird bio, Inc. (Nasdaq: BLUE) today announced that the U.S. Food and Drug Administra

Eiger Announces ILIAD Study Results of Peginterferon Lambda in COVID-19 Published in Lancet Respiratory Medicine 2021

PALO ALTO, Calif., Feb. 8, 2021 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc (Nasdaq:EIGR), a commercial-stage biopharmaceutical company focused on the development and commercialization of foundation